SCIOSCIA, CRESCENZIO
 Distribuzione geografica
Continente #
NA - Nord America 3304
EU - Europa 602
AS - Asia 221
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 4132
Nazione #
US - Stati Uniti d'America 3300
SE - Svezia 259
CN - Cina 193
FR - Francia 85
DE - Germania 73
IT - Italia 57
BE - Belgio 44
GB - Regno Unito 32
FI - Finlandia 20
UA - Ucraina 16
IR - Iran 10
IE - Irlanda 7
IN - India 5
RU - Federazione Russa 5
CA - Canada 3
ID - Indonesia 3
TR - Turchia 3
AT - Austria 2
AU - Australia 2
VN - Vietnam 2
BR - Brasile 1
EU - Europa 1
HK - Hong Kong 1
IL - Israele 1
JP - Giappone 1
LA - Repubblica Popolare Democratica del Laos 1
MN - Mongolia 1
MP - Marianne Settentrionali, isole 1
NL - Olanda 1
PA - Panama 1
RS - Serbia 1
Totale 4132
Città #
Fairfield 487
Chandler 449
Woodbridge 326
Houston 260
Seattle 258
Ann Arbor 253
Nyköping 227
Ashburn 226
Cambridge 197
Wilmington 164
Beijing 70
Dearborn 68
Lawrence 62
Roxbury 62
Jacksonville 61
Brussels 44
Des Moines 39
Inglewood 38
Nanjing 34
Paris 26
San Diego 26
Bari 21
Boardman 21
Brooklyn 21
Princeton 19
Redwood City 17
Hebei 16
Shenyang 9
Dublin 7
Guangzhou 7
San Mateo 7
Hefei 6
Jiaxing 6
Jinan 6
Ardabil 5
Changsha 5
Kunming 5
Leawood 5
London 4
Nanchang 4
Augusta 3
Grumo Appula 3
Toronto 3
Dong Ket 2
Hangzhou 2
Milan 2
Monmouth Junction 2
New Delhi 2
San Francisco 2
Shanghai 2
Shaoxing 2
Stockholm 2
Vienna 2
Alba 1
Baotou 1
Belgrade 1
Canberra 1
Central 1
Chengdu 1
Chongqing 1
Florence 1
Fuzhou 1
Groningen 1
Haikou 1
Indiana 1
Istanbul 1
Jakarta 1
Los Angeles 1
Melbourne 1
Moscow 1
Mumbai 1
Nagold 1
Nanning 1
New York 1
Oklahoma City 1
Paracambi 1
Pars 1
Saipan 1
Taian 1
Taizhou 1
Taranto 1
Tel Aviv 1
Tianjin 1
Trento 1
Ulan Bator 1
Washington 1
Xian 1
Zhengzhou 1
Totale 3632
Nome #
Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients 109
Leucocytoclastic vasculitis as onset symptom of ulcerative colitis 104
Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy 104
null 101
Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: A case series and review of the literature 99
Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA 97
null 97
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register 96
Diffusion and applications of musculoskeletal ultrasound in Italian Rheumatology Units 93
Old and new antirheumatic drugs and the risk of hepatotoxicity 91
Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response 89
A knowledge-based framework enabling decision support in RFID solutions for healthcare 85
null 84
null 82
null 82
AB0618 A unique ultrasound pattern of adipose tissue in systemic sclerosis patients: a comparison with rheumatoid arthritis patients and healthy controls. two sides of adipose tissue involvement in systemic chronic inflammatory diseases 81
AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease 81
ANTI-TNFA THERAPY IN PSORIATIC ARTHRITIS: DIFFERENT RATE OF REMISSION IN POLYARTICULAR AND OLIGOARTICULAR SUBSETS 81
Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab 80
null 79
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 79
Ultrasonography in the diagnosis and management of patients with inflammatory arthritides 77
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 76
AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1 76
AB1114 Three Years Experience with “Sustain”, an Extra-Hospital Infusion Programme for Patients with Rheumatoid Arthritis Treated with Abatacept 75
null 73
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 68
The italian MSUS study group recommendations for the format and content of the report and documentation in musculoskeletal ultrasonography in rheumatology 67
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 67
AB0369 Adult-onset still’s disease treatment predictors at 1-year follow-up in a single rheumatologic centre experience 66
SAT0212 Pericardial Effusion Related To Systemic Sclerosis: A Possible Contribution of The Serum Levels of Adipokines and Interleukines 66
null 66
SAT0216 Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings 65
FRI0110 Methotrexate monotherapy in real life: a drug survival analysis. comparison between very early arthritis and early arthritis cohorts 63
SAT0061 Concurrent Ultrasound-Detected Synovitis and Tenosynovitis Predict Flare in Patients with Rheumatoid Arthritis in Clinical Remission 60
Response of cartilage oligomeric matrix protein to monoclonal antibody drugs in patients with rheumatoid arthritis 60
AB0245 PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE) 58
OP0217 Ultrasound-Detected Synovitis and Tenosynovitis Independently Associate with Flare in Patients with Rheumatoid Arthritis in Clinical Remission 57
LIPID PROFILE OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ANTI-TNF-ALPHA DRUGS CHANGES ACCORDING TO DISEASE ACTIVITY RESPONSE 57
Evaluation of Serum Levels of Adipokines and Interleukines in Pericardial Effusion Related to Systemic Sclerosis 54
THU0168 Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis 54
null 53
Osteocalcin production by osteoarthritic osteoblasts after vitamin D stimulation 53
OP0129 Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors 52
SAT0380 FIBROMYALGIA IS THE STRONGEST NEGATIVE PREDICTOR FOR THE ACHIEVEMENT OF EITHER REMISSION AND MINIMAL DISEASE ACTIVITY IN NAIVE PSORIATIC ARTHRITIS PATIENTS STARTING BIOLOGIC DRUGS 52
The treatment of recurrent uveitis with TNF-alpha inhibitors 50
Different joint and skin clinical response of patients with psoriatic arthritis treated with infliximab 49
Integrin expression on human osteoblasts in osteoarthritis 47
Intentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritis 46
null 46
null 45
null 44
Increased Bcl-2/p53 ratio in human articular cartilage: a possible role in regulation of chondrocyte metabolism 42
Serum cartilage oligomeric matrix protein (COMP) following infliximab treatment in patients with rheumatoid arthritis: Analitical performances and clinical correlations 41
Infliximab therapy in patients with rheumatic disease and HCV chronic infection 41
Use of etanercept in the treatment of dermatomyositis: a case series 37
Leukocytoclastic vasculitis as onset symptom of ulcerative colitis 36
Giant Cell Tumor of Synovial Sheath: Of Two Cases Treated with Intra-Articular Infiltration of Infliximab 35
COMP serum levels in patients with rheumatoid arthritis before and after infliximab therapy 35
Ultrasound-Detected Tenosynovitis Independently Associates with Flare in Patients with Rheumatoid Arthritis in Clinical Remission 34
Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey 29
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE) 27
Correction to: Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE) (Clinical Rheumatology, (2018), 37, 3, (667-675), 10.1007/s10067-018-3989-2) 24
Repeated infusions of low-dose infliximab plus methotrexate in psoriathic arthrtritis: immediate benefitis are not maintained after discontinuation of inlfiximab 23
Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: A systematic literature review 21
Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: Results by Italian DELphi in psoriatic arthritis (IDEA) 20
Economical Evaluation of the Sustain Program for the Out-of-Hospital Administration of Abatacept for Rheumatoid Arthritis 20
Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis 16
Ultrasonography in psoriatic arthritis: Which sites should we scan? 14
Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: Results from the observational study STARTER of the Italian Society for Rheumatology 14
Use of ultrasound in treatment decisions for patients with rheumatoid arthritis: an observational study in Italy 12
Influence of TNF- α inhibition on oxidative stress of rheumatoid arthritis patients 9
The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: The STARTER study 7
L'obésité diminue le maintien thérapeutique des traitements biologiques de seconde ligne après échec d'un anti-TNF de première ligne au cours de la polyarthrite rhumatoïde 5
Totale 4278
Categoria #
all - tutte 8961
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8961


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20183 0000 00 00 0201
2018/2019273 0031 010 016 10459692
2019/20201387 125272673 92245 219181 191907642
2020/2021739 39894249 7826 91102 43796041
2021/2022537 3941825 2640 1523 244479173
2022/20231001 11415082116 113130 36114 146000
Totale 4278